Â鶹ӳ»­

How to  Apply:

The Lymphoma/Myeloma Fellowship Program accepts applications for positions from August 1 through October 1 annually.

The deadline for submission of applications for the 2026-2027  Academic
Year is October 1, 2025. The Lymphoma/Myeloma Fellowship Program academic cycle is annually from July 1 through June 30; late starts are not permitted.

All application contingencies must be finalized prior to the deadline.
Incomplete applications and late inquiries will not be accepted.

• Applications are accepted through the Lymphoma/Myeloma Educational Program
  Office and are available on a highly competitive basis.
• To initiate the application process, please email a current CV to lmfoucheaux@mdanderson.org  with the
  following documents listed below.
• The application checklist provides information regarding the required
  documents to submit with your application and instructions to request documents
  from external entities to submit to our clinical fellowship program.
• Interviews will tentatively be conducted upon completion of all application
  requirements and, if chosen, to move forward in the application and selection
  processes.

MD Anderson Cancer Center¡¯s Graduate Medical Education Office requires the following documentation to process an applicant for the Lymphoma/Myeloma Fellowship Program:

Application Checklist 

Application form:

• Complete the application form and email the application and all supporting documents to Lisa Foucheaux (lmfoucheaux@mdanderson.org, 713-745-4247). Documents must be received by October 1, 2025 of the year preceding the appointment date.  

The fellowship aligns its goals and objectives with the Accreditation Council for Graduate Medical Education's (ACGME) six core competencies to ensure comprehensive training and development of fellows in the field of Lymphoma-Myeloma.

Patient Care

Our program emphasizes providing fellows with comprehensive training in state-of-the-art clinical care for adult patients with lymphomas and plasma cell malignancies. Fellows will gain hands-on experience in both inpatient and outpatient settings, participating in the diagnosis, treatment, and long-term follow-up care of patients.

Medical Knowledge

Through structured educational activities, including lectures, journal clubs, and case conferences, fellows will acquire a thorough understanding of the pathophysiology, diagnosis, and management of lymphomas and plasma cell malignancies in adult patients. Fellows will also engage in research endeavors to deepen their medical knowledge and contribute to advancing the field.

Practice-Based Learning and Improvement

Fellows will develop critical thinking and problem-solving skills through active participation in patient care, research projects, and scholarly activities. They will receive mentorship from experienced faculty members to continually assess and enhance their clinical practice and research endeavors.

Interpersonal and Communication Skills

Fellows will refine their communication skills to effectively interact with patients, families, and interdisciplinary healthcare teams. They will learn to convey complex medical information in a clear and empathetic manner, fostering meaningful relationships with patients and facilitating collaborative care.

Professionalism

Our program instills values of professionalism, integrity, and ethical conduct in fellows, preparing them to uphold the highest standards of patient care, research integrity, and professional responsibility. Fellows will learn to navigate challenging ethical dilemmas and demonstrate respect, compassion, and cultural sensitivity in their interactions with patients and colleagues.

Systems-Based Practice

Fellows will gain insight into the healthcare system's structure and function, learning to navigate complex healthcare environments and advocate for optimal patient outcomes. They will collaborate with interdisciplinary teams to improve patient care quality, safety, and efficiency while also understanding the socioeconomic and cultural factors influencing healthcare delivery.

By integrating these core competencies into our fellowship program, we aim to produce highly skilled and compassionate Lymphoma-Myeloma specialists who are equipped to excel in clinical practice, research, and leadership roles within academic medicine. Our fellows will emerge from the program with the knowledge, skills, and professionalism necessary to make meaningful contributions to the field of lymphomas and plasma cell malignancies, and provide exceptional care to patients and their families.

MENTORSHIP

• A mentorship is a relationship between two people where the individual with more experience, knowledge, and connections is able to pass along what they have learned to a more junior individual within a certain field. 
• The mentor benefits because they are able to lead the future generation in an area they care about and ensure the best practices are passed along
• The mentee benefits because they have proven they are ready to take the next step in their career and can receive the extra support needed to make that advancement.

Clinical Research: We provide a 3-day course on Clinical Research Methodology which includes the following: small group sessions with expert faculty that will focus on clinical research design, statistical design, biomarker trial design, utilizing big data, implementation and analysis, grant writing tips and strategies; and development of a clinical study design with specific aims. This will be followed by monthly follow-up meetings. Fellows will work closely with faculty members involved in clinical research and be expected to participate in clinically-based research projects; research is performed at least 2 days per week. Translational (bench-to-bedside) research opportunities are also available. Fellows are encouraged to present their research at national meetings. 

Clinical Practice: Our program includes intense training in the care of patients with lymphoma or myeloma through working directly with faculty members. Fellows will have 6 weeks of inpatient service completed on a 1-week rotation service; the remainder of the time is spent in outpatient clinic (2 days each week). There is an option for fellows to receive intense training in the care of patients enrolled in clinical trials, including patients in CAR T-cell programs.

Mentoring: Each fellow will be assigned a research mentor and a career development mentor who are clinical faculty members. These mentors will meet regularly with the fellows during the year.

Fellows will attend daily and weekly conferences including planning clinics, research conferences, case study conferences, institutional grand rounds, and hematology grand rounds.  Fellows will also attend formal didactic lectures presented by faculty members, including hematology didactic lectures, and didactic lectures on lymphoma/myeloma disease states and subtypes. During this program, Fellows will develop long-term mentoring and peer-to-peer relationships.

This program averages 10 applicants per year, and fellows have enjoyed lots of success. Past graduates include faculty at the following academic institutions:

• MD Anderson Cancer Center
• Memorial Sloan Kettering Cancer Center
• Ohio State University Comprehensive Center
• University of Western Australia
• Allegheny General Hospital, Pittsburgh
• University of Michigan Health, Rogel Cancer Center
• Kidwai Memorial Institute of Oncology, Bangalore, India
  

Dai Chihara; 2014 - 2015

Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR.
Expert Rev Anticancer Ther. 2015 May;15(5):531-44.

Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE.
Br J Haematol. 2016 Jan;172(1):80-8.

Yoshida N, Chihara D.
Curr Treat Options Oncol. 2015 Feb;16(2):7.

Utsunomiya A, Choi I, Chihara D, Seto M.
Cancer Sci. 2015 Apr;106(4):344-51.

Chihara D, Oki Y.
Expert Opin Biol Ther. 2014 Oct;14(10):1519-26.

Chihara D, Ito H, Matsuo K.
Rinsho Ketsueki. 2015 Apr;56(4):366-74.

Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y.
Br J Haematol. 2015 Nov;171(4):509-16.

Chan Cheah; 2014- 2015

Cheah CY, Oki Y, Fanale MA.
Am Soc Clin Oncol Educ Book. 2015:e468-78.

Cheah CY, Fowler NH, Neelapu SS.
Curr Opin Oncol. 2015 Sep;27(5):384-91.

Cheah CY, Seymour JF.
Curr Oncol Rep. 2015 Jun;17(6):25.

Vishwanath Sathyanarayanan; 2015 - 2016

Sathyanarayanan V, Neelapu SS.
Mol Oncol. 2015 Dec;9(10):2043-53.

Sathyanarayanan V, Hagemeister F.
Rinsho Ketsueki. 2016;57(10):2049-2053.

Lakshmaiah KC, Rachan Shetty KS, Sathyanarayanan V, Lokanatha D, Abraham LJ, Babu KG.J
Cancer Res Ther. 2015 Oct-Dec;11(4):857-61.

Sathyanarayanan V, Foo WC, Fanale M, Westin
J.Clin Lymphoma Myeloma Leuk. 2016 May;16(5):e65-70.

Raphael Steiner; 2016 - 2017

Steiner RE, Manasanch EE.
Onco Targets Ther. 2017 Feb 15;10:895-907.

Steiner RE, Orlowski RZ, Lee HC.
Acta Haematol. 2018;139(1):67-70.

Maria Chaudhry; 2016 - 2017

Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE.
Leuk Lymphoma. 2019 Apr;60(4):964-970.

Samer Tabchi; 2017 ¨C 2018

Nair R, Tabchi S, Hagemeister F.
N Engl J Med. 2017 Dec 28;377(26):2605.

Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE.
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):560-569.

Ranjit Nair; 2017 - 2018

Nair R, Neelapu SS.
Best Pract Res Clin Haematol. 2018 Sep;31(3):293-298.

Nair R, Tabchi S, Hagemeister F.
N Engl J Med. 2017 Dec 28;377(26):2605.

Dahlia Sano; 2018 ¨C 2019

Khan U, Hadid T, Ibrar W, Sano D, Al-Katib A.
J Clin Med Res. 2017 Mar;9(3):213-215. doi: 10.14740/jocmr2929w. Epub 2017 Jan 25.PMID: 28179969

Melody Becnel; 2019 - 2020

Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH.
Br J Haematol. 2019 Jun;185(5):874-882.

Becnel MR, Nastoupil LJ.
Curr Treat Options Oncol. 2018 May 24;19(7):32. doi: 10.1007/s11864-018-0550-0.PMID: 29796824

Collin Chin; 2019 ¨C 2020

Chin CK, Nastoupil LJ.
Hematol Oncol Clin North Am. 2020 Aug;34(4):743-756.

Chin CK, Hall S, Green C, Van Hazel G, Spagnolo D, Cheah CY.
Eur J Cancer. 2019 Jul;115:84-87.

Lewis KL, Chin CK, Manos K, Casey J, Hamad N, Crawford J, Ho SJ, Issa S, Grigg A, Wood P, Gandhi MK, Do B, Nastoupil L, Hawkes EA, Cheah CY.
Br J Haematol. 2020 Jul 16.

Wight JC, Yue M, Keane C, Johnston A, Linton K, Chin C, Wai SH, Talaulikar D, Gasiorowski R, Cheah CY, Gregory GP, Dickinson M, Minson A, Coombes C, Ku M, Lam S, Hawkes EA.
Br J Haematol. 2019 Oct;187(2):174-184.

 
Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ.
Leuk Lymphoma. 2020 Dec;61(12):2985-2989.

Maliha Khan; 2020 ¨C 2021

Gilani JA, Ashfaq MA, Mansoor AE, Abdul Jabbar A, Siddiqui T, Khan M.
Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1691-1699.

Tariq S, Tariq S, Khan M, Azhar A, Baig M.
Cureus. 2020 Jun 29;12(6):e8908.

Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH.
Leuk Lymphoma. 2019 Dec;60(14):3536-3543.

Schinke C, Boyle EM, Ashby C, Wang Y, Lyzogubov V, Wardell C, Qu P, Hoering A, Deshpande S, Ryan K, Thanendrarajan S, Mohan M, Yarlagadda N, Khan M, Choudhury SR, Zangari M, van Rhee F, Davies F, Barlogie B, Morgan G, Walker BA.
Blood Cancer J. 2020 Jun 19;10(6):70.

Mohammad Alomari; 2021 ¨C 2022

Hitawala A, Flores M, Alomari M, Kumar S, Padbidri V, Muthukuru S, Rahman S, Alomari A, Khazaaleh S, Gopalakrishna KV, Michael M.
Cureus. 2020 Apr 22;12(4):e7776.

Sushanth Gouni; 2022 ¨C 2023

Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Watson G, Ayers A, Neelapu SS, Khurana A, Lin Y, Iqbal M, Merryman RW, Strati P.
Blood Adv. 2022 May 10;6(9):2757-2762.

Gouni S, Strati P, Toruner G, Aradhya A, Landgraf R, Bilbao D, Vega F, Agarwal NK.
Leuk Lymphoma. 2022 Jun;63(6):1302-1313.

Ash Gurumurthi; 2022 ¨C 2023

Gurumurthi A, Westin JR, Subklewe M.
Blood Adv. 2023 Apr 10:bloodadvances.2022009066.

Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P.
Leuk Lymphoma. 2024 May;65(5):669-673.

Charles Goulin; 2023-2024

Zhang JR, Wu SY, Jain P, Ok CY, Yan F, Chen W, Oriabure O, Dabaja B, Gunther J, Fang P, Pinnix C, Wang ML, Gaulin C.
Leuk Lymphoma. 2024 Jul 7:1-4. doi: 10.1080/10428194.2024.2374457. Online ahead of print.

Anath Lionel; 2023-2024

Lionel AC, Neelapu SS.
Blood Adv. 2024 Jun 25;8(12):3311-3313. 

Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P.
Leuk Lymphoma. 2024 May;65(5):669-673. d

Lionel AC, Westin
J.Curr Oncol Rep. 2023 Nov;25(11):1387-1396.